Voor de beste behandeling van patiënten met kanker, werken we samen met onderzoekers en behandelaars in heel Nederland.

Hartwig Medical Foundation helpt het ontstaan van kanker en de behandeling daarvan beter te begrijpen.

Hartwig Medical Foundation verzamelt genetische en klinische gegevens en stelt deze beschikbaar voor onderzoek.

Het ultieme doel is dat elke patiënt een gepersonaliseerde behandeling krijgt, gebaseerd op het DNA van de tumor.

FOCUS GROUP STRUCTURAL VARIANTS AND GENE FUSIONS

Cancer affects millions of people worldwide. Next-generation DNA sequencing technologies have taken central stage in cancer research and this has led to the discovery of numerous novel DNA mutations, alterations and mechanisms that underlie disease initiation and metastasis. Genome sequencing is now starting to become part of a routine workflow for cancer diagnostics and potentially enables fine-tuned treatment strategies tailored towards the unique mutational profile of an individual’s (metastatic) cancer genome.

Despite the massive production of cancer genome sequences, detection and interpretation of structural genomic variations and copy number alterations in these data is lagging behind due to computational and algorithmic challenges. The Structural Variation and Gene Fusions Focus Group proposes to develop novel analytical and computational frameworks that lead to comprehensive detection, annotation and interpretation of structural variations in cancer genomes, taking intratumoral heterogeneity, tumor purity and microenvironment of clinical specimens into account. By exploiting the large amount of cancer genome sequencing data generated by Hartwig Medical Foundation, the group will attempt to identify novel structural variations that drive cancer development and metastasis, determine progression and response to treatment or form targets for new treatment opportunities.

 

Chair
Wigard Kloosterman, UMC Utrecht

Lead researchers
Wigard Kloosterman, UMC Utrecht
Jeroen de Ridder, UMC Utrecht
Bauke Ylstra, VUMC

Associated researchers
Sanne Abeln, VU

Remond Fijneman, NKI/AvL
Guido Jenster, EMC
Roel Glas, NKI en VU
Victor Guryev, UMCG
Alexander Schönhuth, UU/CWI
Tom van Wezel